The pharmacological action and duration of action of a drug are closely related to the metabolism. For example, the reduction of zonisamide, an anticonvulsant, to 2-sulfamoylacetylphenol (SMAP) is a detoxification reaction, and the reductive ring-opening reaction is catalyzed by aldehyde oxidase and cytochrome P450. [1] [2] [3] In contrast, the reduction of sulindac, an anti-inflammatory agent, to sulindac sulfide is an activation step, and is catalyzed by aldehyde oxidase, but not cytochrome P450. 4, 5) Imipramine N-oxide is also reduced to an active parent drug, imipramine by aldehyde oxidase and cytochrome P450 (Fig. 1) . 6, 7) Aldehyde oxidase (EC 1.2.3.1), a cytosolic enzyme, contains FAD, molybdenum and iron-sulfur center, and is closely related to xanthine oxidase. 8, 9) The enzyme can catalyze the oxidation of a number of aldehydes and nitrogenous heterocyclic compounds. 8, 9) In humans, benzaldehyde and N 1 -methylnicotinamide oxidase activities based on aldehyde oxidase were reported. 10, 11) Moreover, the enzyme in the presence of its electron donor can mediate the reduction of a variety of compounds such as sulfoxides, 5) N-oxides, 6, 12) epoxides, 19) aromatic nitro compounds 20,21) and 1,2-benzisoxazole derivatives.
trosamines, 13) hydroxamic acids, 14, 15) azo dyes, 16, 17) oximes, 18) epoxides, 19) aromatic nitro compounds 20, 21) and 1,2-benzisoxazole derivatives.
3) However, it has been reported that a marked species difference exists in the oxidase activity of the enzyme. 8, 9) For example, high aldehyde oxidase activity is observed in rabbit and guinea pig livers. 8, 9, 22) In contrast, aldehyde oxidase activity is not detected in dogs. We also showed a marked species difference of the reductase activity of the enzyme. High reductase activity towards N-oxide compounds, epoxides and 1,2-benzoisoxazole derivatives was observed in rabbits. In contrast, relatively low activity was observed in rats and mice. 3, 6, 12, 19) In monkeys, which are often used as a model animal for human therapy, aldehyde oxidase activity in liver cytosol was observed as phthalazine, benzaldehyde or N 1 -methylnicotinamide oxidase activity. 10, 23, 24) However, the drug-reductase activity catalyzed by this enzyme in monkeys has not been reported. In this study, the drug-reducing activity of aldehyde oxidase in monkey liver was examined using zonisamide, sulindac and imipramine N-oxide as substrates. Liver Preparations The livers of animals were immediately perfused with 1.15% KCl and homogenized in 4 volumes of the KCl solution, using a Potter-Elvehjem homogenizer. Microsomes and cytosol were obtained from the homogenate by successive centrifugation at 9000ϫg for 20 min and 105000ϫg for 60 min. The microsomal fraction was washed by resuspension in the KCl solution and resedimentation for 60 min at 105000ϫg for 60 min. Protein contents in liver preparations were determined by the method of Lowry et al.
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25)
Assay of Reductase Activity The incubation mixture consisted of 0.5 mmol of zonisamide, sulindac or imipramine N-oxide, 1 mmol of an electron donor and 20-200 ml of liver cytosol equivalent to 4-40 mg wet weight of liver or microsomes equivalent to 100 mg of liver in a final volume of 1 ml of 0.1 M K,Na-phosphate buffer (pH 7.4). The incubation was performed using a Thunberg tube under anaerobic conditions. The side arm contained a substrate and the body contained all other components. The tube was gassed for 3 min with nitrogen, evacuated with an aspirator for 5 min, and again gassed with nitrogen. The reaction was started by mixing the components of the side arm and the body, and incubation was continued for 10 min at 37°C. In the case of zonisamide, the incubation mixture, after the addition of 10 mg of phenacetin as an internal standard and 2 ml of acetonitrile, was centrifuged. An aliquot of the supernatant was subjected to HPLC as described below. In the case of sulindac, the incubation mixture, after the addition of 0.1 ml of 1 N HCl and 10 mg of phenothiazine as an internal standard, was extracted once with 5 ml of ethyl acetate and the extract was evaporated to dryness in vacuo. The residue was dissolved in 0.1 ml of methanol and then subjected to HPLC as described below. In the case of imipramine N-oxide, the mixture, after the addition of 0.1 ml of 1 N NaOH and 10 mg of phenacetin as an internal standard, was extracted once with 5 ml of ethyl acetate and the extract was evaporated to dryness in vacuo. The residue was dissolved in 0.1 ml of methanol and then subjected to HPLC as described below.
HPLC HPLC was performed on an L-6000 chromatograph (Hitachi, Tokyo, Japan). In the case of zonisamide, a 150 mmϫ4.6 mm inertsil ODS-3 column (GL Science, Tokyo, Japan) was used with a mobile phase of acetonitrile-0.1 M KH 2 PO 4 (3 : 7) at a flow rate of 0.5 ml/min. The detection wavelength was 254 nm. The elution times of SMAP, zonisamide and phenacetin were 8.2, 9.0 and 11.7 min, respectively. In the case of sulindac, a 130 mmϫ4 mm Lichrosphere 100RP-18 column (Merck, Darmstadt, Germany) was used with acetonitrile-0.1 M KH 2 PO 4 (1 : 1) at a flow rate of 0.3 ml/min and the detector was operated at a flow rate of 0.3 ml/min at a wavelength of 254 nm. The elution times of sulindac, phenothiazine and sulindac sulfide were 7.0, 38.2 and 45.2 min, respectively. In the case of imipramine Noxide, a 150 mmϫ4.6 mm Inertsil ODS-3 column was used with acetonitrile-0.1 M KH 2 PO 4 (3 : 7) at a flow rate of 0.5 ml/min and the detector was operated at a wavelength of 254 nm. The elution times of phenacetin, imipramine and imipramine N-oxide were 15.8, 37.2 and 42.0 min, respectively. The amounts of reduction products formed were determined from the peak areas.
RESULTS AND DISCUSSION
The time courses of the reduction of zonisamide to SMAP by liver cytosols from monkeys and rabbits were examined in the presence of 2-hydroxypyrimidine under anaerobic conditions. SMAP was linearly generated from zonisamide by both liver cytosols up 20 min. However, the activity of monkey liver cytosol was about 7-fold higher than that of rabbit liver cytosol, which is often used for metabolic studies of aldehyde oxidase (Fig. 2) .
Monkey liver cytosol exhibited the zonisamide reductase activity in the presence of 2-hydroxypyrimidine or benzaldehyde, an electron donor to aldehyde oxidase. However, xanthine, an electron donor to xanthine oxidase, was not effective for the reduction. NADH or NADPH, an electron donor to DT-diaphorase, was also not effective (Fig. 3A) . The reductase activity with 2-hydroxypyrimidine was inhibited by menadione, cupric sulfate, chlorpromazine, amytal, b-estradiol and dicumarol, which are inhibitors of aldehyde oxidase. 26) However, the activity was not inhibited by oxypurinol, a potent inhibitor of xanthine oxidase (Fig. 3B) . These observations suggest that the reduction of zonisamide by monkey liver cytosol is mainly due to aldehyde oxidase.
Monkey liver cytosol also exhibited significant reductase activities toward sulindac and imipramine N-oxide in the presence of 2-hydroxypyrimidine. These reductase activities, including zonisamide reductase, of monkey liver cytosol were the highest among the animals examined in this study. Dog liver cytosol exhibited no reductase activity toward these (Fig. 4) . Sulindac and imipramine N-oxide reductase activities of monkey liver cytosol were also inhibited by b-estradiol (data not shown).
When zonisamide reductase activity of monkey liver cytosol in the presence of 2-hydroxypyrimidine was compared with that of liver microsomes in the presence of NADPH, the former was about 40-fold higher than the latter (Fig. 5) . Similarly, the imipramine N-oxide reductase activities of liver cytosol and microsomes were 128.5 and 18.3 nmol/10 min/mg protein, respectively.
Based on the present results, it appears that high levels of aldehyde oxidase activity exist in monkey liver cytosol. In monkeys, aldehyde oxidase functions as a major reductase toward many types of drugs such as zonisamide, sulindac and imipramine N-oxide. The cytochrome P450, another drug reductase in mammalian liver, plays a lesser role as a reductase toward xenobiotics in the monkey. Each value represents the mean of three experiments. The drug was incubated with monkey liver cytosol in the presence of 2-hydroxypyrimidine or with the liver microsomes in the presence of NADPH under anaerobic conditions as described under Materials and Methods.
